AXL1717
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Purpose Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation…
Abstract Background: The primary objective of this study was to compare the progression-free survival (PFS) at 12 weeks between…
Background: The aim of the present study was to investigate any prognostic value of pre-treatment anemia, leukocytosis and…
Abstract
AXL1717 is an orally bioavailable IGF-1R pathway modulator that has been shown to have anti-tumoral effects. The…
8091 Background: AXL1717 (picropodophyllin) is small molecule that inhibits the IGF-1R signaling pathway as well as suppresses…
Abstract Background. Inhibition of the Insulin-like Growth Factor-1 receptor (IGF-1R) has resulted in extensive anti-tumor…
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL
Background
The incidence of lung cancer has increased…
e13019 Background: Inhibition of the insulin-like growth factor-1 receptor (IGF-1R) has resulted in extensive antitumor effects…